Though early evidence supports the addition of the PARP inhibitor veliparib to bendamustine and rituximab in B-cell lymphomas49, the role for PARP inhibitors in diffuse large B-cell lymphoma is still under investigation. The gene discussed is PARP1; the disease is diffuse large B-cell lymphoma.